GSK plc (NYSE:GSK) Shares Bought by Brookstone Capital Management

Brookstone Capital Management grew its position in GSK plc (NYSE:GSK) by 19.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 31,701 shares of the pharmaceutical company’s stock after acquiring an additional 5,244 shares during the period. Brookstone Capital Management’s holdings in GSK were worth $1,072,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of GSK. FMR LLC raised its holdings in GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares during the period. Fisher Asset Management LLC increased its position in shares of GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after buying an additional 870,449 shares in the last quarter. Clifford Capital Partners LLC raised its stake in shares of GSK by 14.3% during the 3rd quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock worth $16,747,000 after buying an additional 51,378 shares during the period. Cerity Partners LLC lifted its position in shares of GSK by 61.8% during the 3rd quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock valued at $17,728,000 after buying an additional 165,556 shares in the last quarter. Finally, Natixis Advisors LLC grew its stake in GSK by 20.0% in the 3rd quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock valued at $20,460,000 after acquiring an additional 83,433 shares during the period. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on GSK. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Monday. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and reduced their target price for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Seven equities research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. Based on data from MarketBeat, GSK currently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Stock Performance

GSK opened at $33.50 on Friday. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.92. The firm has a market capitalization of $69.42 billion, a PE ratio of 21.75, a PEG ratio of 1.44 and a beta of 0.63. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The firm’s 50-day moving average price is $34.14 and its 200 day moving average price is $38.04.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were given a $0.3928 dividend. The ex-dividend date was Friday, November 15th. This is a positive change from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.69%. GSK’s dividend payout ratio is 95.45%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.